[
  {
    "ts": null,
    "headline": "IQVIA Holdings Inc. (IQV) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript",
    "summary": "IQVIA Holdings Inc. (IQV) Citi's 2026 Unplugged MedTech and Life Sciences Access Day February 26, 2026 11:00 AM ESTCompany ParticipantsRonald Bruehlman -...",
    "url": "https://finnhub.io/api/news?id=e996a171290a77b915d149ab443236ea3efd9a120721e30a81297c4b048e7292",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772118469,
      "headline": "IQVIA Holdings Inc. (IQV) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript",
      "id": 139238804,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "IQV",
      "source": "SeekingAlpha",
      "summary": "IQVIA Holdings Inc. (IQV) Citi's 2026 Unplugged MedTech and Life Sciences Access Day February 26, 2026 11:00 AM ESTCompany ParticipantsRonald Bruehlman -...",
      "url": "https://finnhub.io/api/news?id=e996a171290a77b915d149ab443236ea3efd9a120721e30a81297c4b048e7292"
    }
  },
  {
    "ts": null,
    "headline": "IQVIA Holdings (IQV) Rallied on Waning Concerns Over Biotech Funding and Clinical Activity",
    "summary": "Broyhill Asset Management, an investment advisor, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. 2025 witnessed extreme market concentration and a strong focus on artificial intelligence, leaving many sectors behind. The Portfolio, which has been significantly reshaped, now trades at a substantial discount relative to the broader market. […]",
    "url": "https://finnhub.io/api/news?id=ceef5e83861c73090a5135a41ea557e5f2c88c63ec096722fffc0b8f993083cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772114613,
      "headline": "IQVIA Holdings (IQV) Rallied on Waning Concerns Over Biotech Funding and Clinical Activity",
      "id": 139235606,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "IQV",
      "source": "Yahoo",
      "summary": "Broyhill Asset Management, an investment advisor, released its fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. 2025 witnessed extreme market concentration and a strong focus on artificial intelligence, leaving many sectors behind. The Portfolio, which has been significantly reshaped, now trades at a substantial discount relative to the broader market. […]",
      "url": "https://finnhub.io/api/news?id=ceef5e83861c73090a5135a41ea557e5f2c88c63ec096722fffc0b8f993083cc"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons to Sell IQV and 1 Stock to Buy Instead",
    "summary": "Over the last six months, IQVIA’s shares have sunk to $163.04, producing a disappointing 13.2% loss - a stark contrast to the S&P 500’s 6.5% gain. This may have investors wondering how to approach the situation.",
    "url": "https://finnhub.io/api/news?id=520e3f81d0b2e9db18ee3c49635437b85801bbe7f2ffb01bdd8bd1ce31389f07",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772113735,
      "headline": "3 Reasons to Sell IQV and 1 Stock to Buy Instead",
      "id": 139232642,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "IQV",
      "source": "Yahoo",
      "summary": "Over the last six months, IQVIA’s shares have sunk to $163.04, producing a disappointing 13.2% loss - a stark contrast to the S&P 500’s 6.5% gain. This may have investors wondering how to approach the situation.",
      "url": "https://finnhub.io/api/news?id=520e3f81d0b2e9db18ee3c49635437b85801bbe7f2ffb01bdd8bd1ce31389f07"
    }
  },
  {
    "ts": null,
    "headline": "IQVIA to acquire Charles River drug discovery assets",
    "summary": "The expanded offerings will allow IQVIA to serve a broader range of drug modalities and therapeutic areas.",
    "url": "https://finnhub.io/api/news?id=bd93a34295c1aff7a7bb271b0b28ae1f8f0033a3baa0f51431f30a990d218c0b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772106179,
      "headline": "IQVIA to acquire Charles River drug discovery assets",
      "id": 139231063,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "IQV",
      "source": "Yahoo",
      "summary": "The expanded offerings will allow IQVIA to serve a broader range of drug modalities and therapeutic areas.",
      "url": "https://finnhub.io/api/news?id=bd93a34295c1aff7a7bb271b0b28ae1f8f0033a3baa0f51431f30a990d218c0b"
    }
  },
  {
    "ts": null,
    "headline": "Dassault Systèmes: Beyond The AI Hype, 'Diworsification' Is The Core Issue",
    "summary": "Dassault Systèmes: Beyond The AI Hype, 'Diworsification' Is The Core Issue",
    "url": "https://finnhub.io/api/news?id=eefd041d3705be3f02178bd0821da674e023e8605ba2285823fa51683e492c44",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772092800,
      "headline": "Dassault Systèmes: Beyond The AI Hype, 'Diworsification' Is The Core Issue",
      "id": 139231372,
      "image": "",
      "related": "IQV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=eefd041d3705be3f02178bd0821da674e023e8605ba2285823fa51683e492c44"
    }
  },
  {
    "ts": null,
    "headline": "IQVIA Acquisition Expands Drug Discovery Role And Highlights Valuation Gap",
    "summary": "IQVIA Holdings (NYSE:IQV) agreed to acquire discovery services assets from Charles River Laboratories. The deal focuses on in vitro discovery services and a small molecule AI platform that support non animal research methods. The transaction is intended to expand IQVIA's end to end drug discovery capabilities and broaden its therapeutic coverage. For investors watching NYSE:IQV, this move connects directly to IQVIA's role as a data driven partner for biopharma and healthcare clients. The...",
    "url": "https://finnhub.io/api/news?id=f40dfd5132b5f2e09b99c042e8e849e4629b4b608e048a11adcfb5def93b459d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1772086165,
      "headline": "IQVIA Acquisition Expands Drug Discovery Role And Highlights Valuation Gap",
      "id": 139229607,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "IQV",
      "source": "Yahoo",
      "summary": "IQVIA Holdings (NYSE:IQV) agreed to acquire discovery services assets from Charles River Laboratories. The deal focuses on in vitro discovery services and a small molecule AI platform that support non animal research methods. The transaction is intended to expand IQVIA's end to end drug discovery capabilities and broaden its therapeutic coverage. For investors watching NYSE:IQV, this move connects directly to IQVIA's role as a data driven partner for biopharma and healthcare clients. The...",
      "url": "https://finnhub.io/api/news?id=f40dfd5132b5f2e09b99c042e8e849e4629b4b608e048a11adcfb5def93b459d"
    }
  }
]